#United States #biotechnology #ISO Certification #Miramar #Kimera Labs

Kimera Labs Achieves ISO Certifications to Enhance Quality Control

Kimera Labs, Inc., a clinical-stage biotechnology company focused on the research and production of placental mesenchymal stem cell-derived exosomes, has recently announced a significant milestone in its operational excellence. The company has successfully integrated three critical ISO certifications—ISO 9001:2015, ISO 13485:2016, and ISO 22716:2007—into its manufacturing processes at the Miramar facility in Florida. This strategic move reflects Kimera Labs' unwavering dedication to maintaining high-quality standards across its product offerings.

A Unified Quality Management System

The certifications have been set up as a cohesive quality management system, effectively overseen within Kimera Labs’ extensive 27,000-square-foot manufacturing space. This new quality framework applies to various programs, notably its investigational manufacturing operations alongside its commercial cosmetic product lines, including the Kiara, Luxir, and Vive brands.

Kimera Labs’ CEO, Dr. Duncan Ross, emphasized the importance of these certifications, stating, "Our quality program has consistently delivered a safe, pure, and highly characterized exosome product since its inception in 2015. These ISO certifications reinforce our commitment to excellence across clinical, medical device, and cosmetic industries."

The concurrent pursuit of these ISO certifications was primarily motivated by the complexities of managing diverse manufacturing activities within a single quality system. This encompasses regulated manufacturing for investigational new drug (IND) applications, as well as good manufacturing practices (GMP) compliant productions tailored for cosmetic products.

Understanding the ISO Standards

ISO 9001:2015

ISO 9001:2015 provides a framework for effective process management and ongoing improvement. By adhering to these standards, Kimera Labs ensures systematic quality assessments and continuous enhancement in all operational aspects.

ISO 13485:2016

This certification pertains specifically to medical devices and life sciences manufacturing, underscoring the stringent requirements necessary for producing safe and effective products destined for clinical use. ISO 13485:2016 empowers Kimera Labs to navigate the highly regulated landscape of healthcare technology while delivering top-tier products.

ISO 22716:2007

Focusing on cosmetics, ISO 22716:2007 delineates the standards for good manufacturing practice, ensuring that products are manufactured, controlled, stored, and distributed under stringent quality guidelines. This step is crucial for the integrity of Kimera Labs' cosmetic offerings, which cater to consumers with high-quality expectations.

A Commitment to Compliance

With an active Investigational New Drug application and a Phase I safety trial scheduled for completion by the end of Q3 2026, these ISO certifications represent a significant leap forward in expanding the company's compliance infrastructure. By creating a documented and independently verifiable quality framework, Kimera Labs optimally governs all production activities within its facility, effectively assuring compliance in the dynamic landscape of biotechnology and cosmetics.

About Kimera Labs, Inc.

Founded in 2015 and headquartered in Miramar, Florida, Kimera Labs operates with a mission to advance the use of placental mesenchymal stem cell-derived exosomes in both clinical and cosmetic scenarios. The company is dedicated to pushing the boundaries of biotechnological research and setting industry standards for quality and safety.

Through its recent ISO certifications, Kimera Labs not only underscores its commitment to excellence but also reinforces its role as a leader in the biotechnology sector, one that prioritizes innovation, safety, and customer satisfaction.